Loading clinical trials...
Loading clinical trials...
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Eli Lilly and Company
NCT06132828 · Solid Tumor
NCT04570423 · Solid Tumors, Lymphoma
NCT06144671 · Solid Tumor, Adult
NCT07177937 · Small Cell Lung Cancer, Melanoma, and more
NCT07489378 · Very Rare Tumors, Very Rare Cancers, and more
University of Louisville
Louisville, Kentucky
Weill Cornell Medical College
New York, New York
University of Texas MD Anderson Cancer Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions